TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Rate of Accrual
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of patients achieving target CD34+ cells/kg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Surface area of the scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Visual Analogue Scale (VAS) scores
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: Autobiographical subjective score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Evidence of dysphagia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fluid Recommendation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diet Recommendation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lipid/lipoprotein profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Metabolizable energy based on diet and excreta
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Readmission for heart failure within 30-days
Endpoint domain: Mortality/survival
Primary endpoint: Inadequate response to tetracosactin infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lung metastasis
Endpoint domain: Mortality/survival
Primary endpoint: Reduction in Bedwetting episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of stone expulsion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: analgesics consumption
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Reduction of postoperative infection
Endpoint domain: Adverse events/effects
Primary endpoint: Lobene Stain Index of Stain Extent Scores 4 Weeks After Dentifrice Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lobene Stain Index of Stain Area Scores 4 Weeks After Dentifrice Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lobene Stain Index of Stain Composite Scores 4 Weeks After Dentifrice Use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Eradication rate of HP infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in Hemodynamic Variables
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Timed Get Up and Go (TGUG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacokinetic parameters of esomeprazole
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: speech cortical evoked potential
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: FEV1 AUC0-6 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Peak FEV1 Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: structural changes in colon morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: functional changes assessed by MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of anti-drug antibodies (ADA)
Endpoint domain: Adverse events/effects
Primary endpoint: Diffusion properties of the spinal cord
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in crestal bone loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reactive Hyperemic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Persistent organ dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body circumference
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to obtain an erection sufficient for intercourse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of Pirfenidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC[0-t]) of Pirfenidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from Time Zero to Infinity (AUC[0-inf]) of Pirfenidone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to tracheal extubation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Skin incision skewness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: S. aureus transmission
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Abemaciclib Dose-Limiting Toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Cmax of Risperdal® Consta®
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epicritic sensitivity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Thermoalgic sensitivity measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Safety of KRN23 injections
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of KRN23 injections
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lymphocyte subgroups
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in disclosure
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cumulative Incidence of Grade II-IV Acute Graft-Versus-Host Disease (GVHD) at Day 100
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: LDL cholesterol treatment levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change of IGF-I levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Difference of fat-free mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of gE-specific CD4+ T-cells expressing activation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency of VZV-specific CD4+ T-cells expressing activation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-glycoprotein E (gE) antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-VZV antibody concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Adverse Events Related to Study Treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Lag Screw migration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-rated back pain
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Biopsy proven antibody mediated changes and/or TCMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Diagnostic performance of stool and serum CMV PCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of the SNr
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with progression-free disease at 16 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Improvement of pyramidal function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement of bowel-bladder function score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Pharmacokinetics in Aqueous Humor Samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Midline Frontal Theta Power (MFT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in urine polyphenol metabolites excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in plasma polyphenol metabolites concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Efficacy of AT for poor responders
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients who agree to enroll
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Score on Modified Treatment Evaluation Inventory Short Form
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Percentage of patients who complete 5 out of 8 possible Behavioral Activation sessions
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Latency period of anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-Operative Surgical Infection Complication
Endpoint domain: Adverse events/effects
Primary endpoint: Retinal displacement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Serum bactericidal antibody (SBA) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: composite of all-cause death or hospitalizations due to heart failure
Endpoint domain: Mortality/survival
Primary endpoint: Participant Rating of Usefulness of Intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Hospital Consumer Assessment of Healthcare providers and Systems (HCAHPS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Microbiological success
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Confirmed Infant HIV Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Progression to AIDS-defining Illness or Death
Endpoint domain: Mortality/survival
Primary endpoint: maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in vitamin D concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in proportion of patients taking oral anticoagulants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Adverse events in early postoperative period
Endpoint domain: Adverse events/effects
Primary endpoint: Change in total Spastic paraplegia rating scale (SPRS) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of Delirium
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of Delirium
Endpoint domain: Mortality/survival
Primary endpoint: Pathological Anatomic diagnosis (PAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Overall Subject Global Assessment (SGA) of relief of IBS symptoms
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: FLACC Pain Score Greater Than or Equal to 4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality after breast cancer diagnosis
Endpoint domain: Mortality/survival
Primary endpoint: Change in average E'
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Responder rate based on KOOS5
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Picture naming speed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline HbA1c levels of adolescents at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in average daily insulin dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Fugl Myer Motor Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Serum antibody concentrations to toxins A and B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum antibody titers against toxins A and B
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Papule/Pustule Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Cup-to-disc ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Inflammatory stress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of outpatients with low to moderate risk of suicidal recurrence
Endpoint domain: Adverse events/effects
Primary endpoint: AUC inf of azithromycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC last of azithromycin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Antimicrobial Use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of hypothermia induction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maintenance of hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rewarming rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PRU level at 2 hours after clopidogrel loading
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in number of lane maintenance errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of visual scanning errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in number of signalling errors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intestinal lipoprotein production
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in FHHS expenses pertaining to medical costs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in renal volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Sensor Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensor Survival
Endpoint domain: Mortality/survival
Primary endpoint: 7-day Point Prevalence Abstinence From Cigarettes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tissue morphology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Impact on platelet transfusion practice
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Treatment planning time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: 3D-mask confection time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Patient reported adverse events and tolerability of mask
Endpoint domain: Adverse events/effects
Primary endpoint: Endometrial vascularization index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in viral load (HIV-RNA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in lipid parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: hair loss after chemotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of study drug related TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Stress symptomatology
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Frequency of neoatherosclerosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Spirometric response (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Lung volumes (RV, TLC, RV/TLC ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Effect of medications on symptoms of COVID19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of medications on disease severity of COVID19
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of Energy Application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of esophageal thermal lesions
Endpoint domain: Adverse events/effects
Primary endpoint: Total radiofrequency time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Timely patient discharge before 11 am
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Employee satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: proportion of patients becoming HDV-RNA negative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: estimates of physical parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Pure Procrastination Scale (PPS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline in Susceptibility to Temptation Scale (STS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change from baseline in Irrational Procrastination Scale (IPS)
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Algoplus score of pain during the LP procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants that Cross-Over
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants Lost to Follow Up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: neuropsychiatric and neurological safety
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Acute Respiratory Distress Syndrome (ARDS)
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participant Withdrawals Due to Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Static 2-point discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: MATE-3 Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: MATE-6 Score
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of linkage to HIV prevention services
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Quantitated Myocardial Perfusion Reserve After a Delay
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in Cramp Duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Cramp Intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fibroid Perfusion From Baseline at 7 Days Post Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Fibroid Perfusion From Baseline at 28 Days Post Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in BARS total scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: PASI-75 Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Steady state area under the glucose infusion rate profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Retinal Thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cigarette Per Day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PaO2 levels before and during pre-oxygenation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Cognitive Function Composite Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RAVLT score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of discordant films
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Level
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Cataract surgical rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Quality of recovery after surgery
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in ALT level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Change in grade of fatty liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: RNA expression of genes associated with skin disease in affected versus unaffected skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: RNA expression of genes associated with skin disease in healthy skin from HVs versus affected skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: RNA expression of genes associated with skin disease in healthy skin from HVs versus unaffected skin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Correlation between expression levels from tape harvesting and blood samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Recurrence of Atrial Tachyarrhythmia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes